Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04150029
Title A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)
Acronym STIMULUS-AML1
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUS

Facility Status City State Zip Country Details
25Uni of Alabama at Birmingham Birmingham Alabama 35294 United States Details
Yale University School Of Medicine . New Haven Connecticut 06520 United States Details
Uni of Iowa Hospitals and Clinics Univ of Iowa Hosp & Clinic Iowa City Iowa 52242 United States Details
Dana Farber Cancer Institute Dana Farber Cancer Int Boston Massachusetts 02215 United States Details
Mayo Clinic Rochester Dept. of Mayo Clinic (2) Rochester Minnesota 55905 United States Details
Memorial Sloan Kettering Dept. of MSKCC New York New York 10017 United States Details
Weill Cornell Medicine NY-Presb . New York New York 10021 United States Details
Levine Cancer Insitute Carolinas Healthcare System Charlotte North Carolina 28204 United States Details
Duke Univ Medical Center . Durham North Carolina 27710 United States Details
Chattanooga Onc And Hem Assoc PC Tennessee Oncology Chattanooga Chattanooga Tennessee 37404 United States Details
MD Anderson Cancer Center/University of Texas MD Anderson Houston Texas 77030 United States Details
Huntsman Cancer Institute Univ of Utah . Salt Lake City Utah 84112 0550 United States Details
Novartis Investigative Site Clayton Victoria 3168 Australia Details
Novartis Investigative Site Vancouver British Columbia V5Z 1M9 Canada Details
Novartis Investigative Site Toronto Ontario M5G 1Z6 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1E2 Canada Details
Novartis Investigative Site Paris 10 75475 France Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Milano MI 20162 Italy Details
Novartis Investigative Site Roma RM 00133 Italy Details
Novartis Investigative Site Fukushima city Fukushima 960 1295 Japan Details
Novartis Investigative Site Yamagata 990 9585 Japan Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Kaohsiung 83301 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field